BT-474/HR NTCC?曲妥珠單抗(赫塞汀)耐藥人乳腺癌細胞株Herceptin-Resistant (trastuzumab) human breast tumor cell line

BioVector NTCC Inc.

BT-474: The Parent Cell Line

• Origin: BT-474 cells were originally derived from a breast tumor of a 60-year-old woman with invasive ductal carcinoma.

• Characteristics:

  • Express estrogen and progesterone receptors (ER/PR positive), meaning they are sensitive to hormones.

  • Overexpress HER2 (human epidermal growth factor receptor 2), a protein that promotes cell growth. This makes them relevant for studying HER2-positive breast cancers.

  
  

BT-474/HR: A Resistant Variant

• HR stands for Herceptin-Resistant: Herceptin (trastuzumab) is a targeted therapy that blocks HER2 and is effective in treating many HER2-positive breast cancers. However, some cancers develop resistance to Herceptin.

• Development of Resistance: BT-474/HR cells were created by exposing BT-474 cells to Herceptin over a long period. This selected for cells that were able to survive and grow even in the presence of the drug.

• Significance: BT-474/HR cells are crucial for studying the mechanisms of Herceptin resistance. By comparing these cells to the original BT-474 cells, researchers can identify the changes that allow the cancer cells to evade the drug's effects.

Applications in Research

• Understanding drug resistance: BT-474/HR cells help scientists understand how breast cancer cells become resistant to Herceptin and other HER2-targeted therapies.

• Developing new therapies: These cells can be used to test new drugs and treatment strategies that can overcome Herceptin resistance.

• Personalized medicine: Research with BT-474/HR cells may contribute to developing personalized treatment approaches for patients with HER2-positive breast cancer that has become resistant to Herceptin.

Image

生產廠家Supplier:

BioVector NTCC質粒載體菌株細胞蛋白抗體基因保藏中心

E-mail:BioVector@163.com

http://www.biovector.net